Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101

Schöffski, P; Wozniak, A; Casali, P; Rutkowski, P; Blay, J; Lindner, L; Strauss, S; Anthoney, A; Duffaud, F; Richter, S; Grünwald, V; Leahy, Michael G; Reichardt, P; Sufliarsky, J; van der Graaf, W; Sciot, R; Debiec-Rychter, M; van Cann, T; Marréaud, S; Lia, M; Raveloarivahy, T; Collette, L; Bauer, S

Affiliation

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

Issue Date

2017-09-18

Metadata

Show full item record

Abstract

Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.

Citation

Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". 2017, Ann Oncol

Journal

Annals of Oncology

URI

http://hdl.handle.net/10541/620617

DOI

10.1093/annonc/mdx527

PubMed ID

28950372

Type

Article

Language

ISSN

1569-8041

Collections

All Christie Publications